Breaking News, Collaborations & Alliances

Menarini, Insilico Partner on Novel KAT6A Inhibitor for Oncology

Small molecule KAT6A inhibitor designed using Insilico's AI platform as a potential treatment for hormone sensitive cancers.

The Menarini Group, an international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, along with clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine, entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for ho...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters